GHK-Cu vs BPC-157
Two peptides marketed for “repair” that are often mentioned together but are completely unrelated — one a copper skin peptide, the other a gut-derived tissue peptide.
Different molecules, different evidence. GHK-Cu is a real cosmetic ingredient with topical data; BPC-157 is an unapproved research chemical resting on animal studies. Neither has controlled human evidence for injected healing. This is a factual comparison, not advice.
| GHK-Cu | BPC-157Bepecin | |
|---|---|---|
| What it is | Copper-carrying tripeptide (GHK + Cu) | Synthetic 15-aa gastric peptide |
| Best evidence for | Skin / cosmetic (topical) | Tendon, muscle, gut (animal) |
| Evidence | Topical human data; injected use unstudied | Preclinical (animal); unproven in humans |
| Route | topical (cream, serum) and, outside any approval framework, subcutaneous | subcutaneous, intramuscular; also sold orally without supporting absorption data |
| Doping | Not specifically named | Banned — WADA S0 |
GHK-Cu
A copper-carrying tripeptide the body makes itself, best established as a topical cosmetic ingredient — there is genuine evidence for its effect on skin. Its use as a subcutaneous injection for systemic “repair” is a grey-market extension well beyond where the evidence sits, and injected copper is not risk-free.
BPC-157
A synthetic pentadecapeptide derived from a gastric protein, promoted for tendon, muscle and gut repair. Its animal data is more relevant to those internal tissues than GHK-Cu’s, but it has no controlled human efficacy trials — the case is preclinical. It is more often compared with TB-500.